...
机译:随机化多中心第2期 - 复发难治性骨髓瘤中的吡啶胺,环磷酰胺和地塞米松研究
Univ S Florida Coll Med H Lee Moffitt Canc Ctr &
Res Inst Dept Malignant Hematol 12902 Magnolia;
UCSF Helen Diller Family Comprehens Canc Ctr Myeloma Program San Francisco CA USA;
Univ S Florida Coll Med H Lee Moffitt Canc Ctr &
Res Inst Dept Biostat Tampa FL 33612 USA;
Univ S Florida Coll Med H Lee Moffitt Canc Ctr &
Res Inst Dept Biostat Tampa FL 33612 USA;
Univ S Florida Coll Med H Lee Moffitt Canc Ctr &
Res Inst Dept Malignant Hematol 12902 Magnolia;
Mt Sinai Sch Med Multiple Myeloma Program Tisch Canc Inst New York NY USA;
UCSF Helen Diller Family Comprehens Canc Ctr Myeloma Program San Francisco CA USA;
UCSF Helen Diller Family Comprehens Canc Ctr Myeloma Program San Francisco CA USA;
Mt Sinai Sch Med Multiple Myeloma Program Tisch Canc Inst New York NY USA;
Univ S Florida Coll Med H Lee Moffitt Canc Ctr &
Res Inst Dept Blood &
Marrow Transplantat;
Univ S Florida Coll Med H Lee Moffitt Canc Ctr &
Res Inst Dept Malignant Hematol 12902 Magnolia;
Mt Sinai Sch Med Multiple Myeloma Program Tisch Canc Inst New York NY USA;
Univ S Florida Coll Med H Lee Moffitt Canc Ctr &
Res Inst Dept Blood &
Marrow Transplantat;
Mt Sinai Sch Med Multiple Myeloma Program Tisch Canc Inst New York NY USA;
机译:随机多中心2阶段研究氟三胺,环磷酰胺和地塞米松复发难治性骨髓瘤(Vol 127,PG 2561,2016)
机译:Isatuximab加上氯胺和低剂量的地塞米松与氯胺和低剂量的地塞米松,患者复发和难治性多骨髓瘤(icaria-mm):一个随机的,多型,开放标签,第3期研究
机译:isatuximab加上氯胺和低剂量的地塞米松与氯胺和低剂量地塞米松,在复发和难治性多发性骨髓瘤(icaria-mm)中(icaria-mm):随机,多期中心,开放标签,第3阶段研究(第394 Vol 394,PG 2096,2019)
机译:沙利度胺加上难治性/复发患者中的中间剂量地塞米松
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:MM-003的3期随机研究比较了pomalidomide联合小剂量地塞米松与大剂量地塞米松与大剂量地塞米松在复发/难治性多发性骨髓瘤中的作用以及先前治疗和反应深度对生存率的影响
机译:随机化多中心相2研究荷马磷,环磷酰胺和地塞米松在复发难治性骨髓瘤中